Insider Buying: Quantum-Si incorporated (NASDAQ:QSI) Director Purchases $120,843.00 in Stock

Quantum-Si incorporated (NASDAQ:QSI) Director Charles R. Kummeth bought 138,900 shares of Quantum-Si stock in a transaction dated Friday, August 9th. The stock was acquired at an average cost of $0.87 per share, for a total transaction of $120,843.00. Following the completion of the acquisition, the director now directly owns 323,900 shares in the company, valued at $281,793. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Quantum-Si Price Performance

Shares of QSI opened at $1.02 on Friday. The company has a market capitalization of $144.65 million, a P/E ratio of -1.57 and a beta of 2.89. Quantum-Si incorporated has a one year low of $0.73 and a one year high of $2.47. The business’s 50 day simple moving average is $1.08 and its 200-day simple moving average is $1.50.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Quantum-Si in a report on Friday, May 10th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Quantum-Si during the 2nd quarter worth $25,000. Bank of New York Mellon Corp lifted its holdings in Quantum-Si by 3.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 322,460 shares of the company’s stock worth $339,000 after buying an additional 10,811 shares in the last quarter. Virtu Financial LLC acquired a new position in Quantum-Si during the 1st quarter worth $98,000. Jacobs Levy Equity Management Inc. acquired a new position in Quantum-Si during the 1st quarter worth $998,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Quantum-Si during the 1st quarter worth $27,000. Institutional investors and hedge funds own 39.90% of the company’s stock.

Quantum-Si Company Profile

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.